Cholesterol clinical trials at UCSF

3 in progress, 2 open to eligible people

Cholesterol is a type of fat that travels in the blood. UCSF is evaluating a medicine called inclisiran in children with inherited high cholesterol for safety and effectiveness. UCSF is studying both heterozygous and homozygous inherited forms.

Showing trials for

  • Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

    open to eligible people ages 6-11

    This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to <12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).

    San Francisco, California and other locations

  • Inclisiran in Children With Homozygous Familial Hypercholesterolemia

    open to eligible people ages 2-11

    This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).

    San Francisco, California and other locations

  • VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

    Sorry, in progress, not accepting new patients

    VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.

    San Francisco, California and other locations

Our lead scientists for Cholesterol research studies include .

Last updated: